CenterBook Partners LP Acquires New Stake in Charles River Laboratories International, Inc. $CRL

Charles River Laboratories International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CenterBook Partners acquired a new stake of 17,031 Charles River Laboratories shares, worth approximately $5.0 million. Institutional investors collectively own 98.91% of the company’s stock.
  • Charles River reported quarterly earnings of $3.09 per share, beating the $2.97 consensus, and revenue of $982.73 million, above expectations; revenue declined 2.2% year over year.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $308.17. Company insiders sold 102,299 shares worth about $31.1 million over the past three months.
  • Five stocks to consider instead of Charles River Laboratories International.

CenterBook Partners LP acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 17,031 shares of the medical research company's stock, valued at approximately $5,024,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. North Dakota State Investment Board raised its holdings in Charles River Laboratories International by 2.7% during the 3rd quarter. North Dakota State Investment Board now owns 1,489 shares of the medical research company's stock valued at $439,000 after buying an additional 39 shares during the period. Physician Wealth Advisors Inc. lifted its position in Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company's stock worth $29,000 after buying an additional 55 shares during the last quarter. Activest Wealth Management lifted its position in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company's stock worth $82,000 after buying an additional 57 shares during the last quarter. Choreo LLC boosted its stake in Charles River Laboratories International by 2.8% during the third quarter. Choreo LLC now owns 2,165 shares of the medical research company's stock worth $639,000 after buying an additional 59 shares during the period. Finally, Empirical Finance LLC boosted its stake in Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company's stock worth $333,000 after buying an additional 62 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Activity

In other Charles River Laboratories International news, Director James C. Foster sold 24,042 shares of the firm's stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $11,058,600. This trade represents a 43.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the transaction, the director directly owned 1,438 shares in the company, valued at $410,175.12. This represents a 28.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 102,299 shares of company stock worth $31,050,863. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Up 8.0%

Shares of NYSE:CRL opened at $337.91 on Friday. The business's 50 day moving average is $305.71 and its 200 day moving average is $225.19. The stock has a market cap of $16.19 billion, a P/E ratio of 371.33, a price-to-earnings-growth ratio of 3.14 and a beta of 1.36. Charles River Laboratories International, Inc. has a 52-week low of $146.20 and a 52-week high of $379.63. The company has a quick ratio of 1.04, a current ratio of 1.41 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm's quarterly revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.43 earnings per share. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Saturday. UBS Group increased their target price on shares of Charles River Laboratories International from $357.00 to $387.00 and gave the company a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday, August 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $308.17.

Get Our Latest Research Report on Charles River Laboratories International

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support.

The company's offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions.

Recommended Stories

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines